Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00452439 · ClinicalTrials.gov registry record · Phase 3
A Study of Actonel for the Prevention of Bone Loss
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
NCT00452439: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00452439 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 72 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00452439, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia. The safety of this treatment in patients with ALL or LL will also be studied.
Primary Outcome
bone mineral density (BMD) Mean percent Change in Bone Density from Baseline to 6 months.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DIETARY_SUPPLEMENT Calcium
- DRUG Actonel (Risedronate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2004-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
What the finished NCT00452439 record still lists
NCT00452439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Vitamin D is the first listed.
NCT00452439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00452439 about?
NCT00452439 is a clinical study titled "A Study of Actonel for the Prevention of Bone Loss". The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia. The safety of this treatment in patients with ALL or LL will also be studied.
What is the current status of trial NCT00452439?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2004-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00452439?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), Calcium (DIETARY_SUPPLEMENT), Actonel (Risedronate) (DRUG).
Who is sponsoring clinical trial NCT00452439?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00452439's enrollment target sits among peer trials
72 1780th of 2000 higher than 217 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia